Plimoth Trust Co. LLC Buys 288 Shares of Humana Inc. (NYSE:HUM)

Plimoth Trust Co. LLC boosted its position in shares of Humana Inc. (NYSE:HUM) by 39.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,018 shares of the insurance provider’s stock after buying an additional 288 shares during the quarter. Plimoth Trust Co. LLC’s holdings in Humana were worth $353,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Narus Financial Partners LLC purchased a new stake in shares of Humana in the first quarter worth approximately $2,932,000. Allspring Global Investments Holdings LLC increased its stake in Humana by 255.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 620,793 shares of the insurance provider’s stock worth $215,241,000 after buying an additional 446,124 shares during the period. Diversified Trust Co boosted its position in Humana by 30.1% in the 1st quarter. Diversified Trust Co now owns 2,709 shares of the insurance provider’s stock valued at $939,000 after buying an additional 627 shares during the period. Financial Partners Group LLC purchased a new stake in shares of Humana in the first quarter valued at approximately $6,352,000. Finally, D.B. Root & Company LLC purchased a new position in Humana during the 1st quarter worth $351,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

NYSE HUM opened at $362.85 on Thursday. The company has a market cap of $43.72 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 2.16 and a beta of 0.51. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The stock’s fifty day moving average price is $345.69 and its 200 day moving average price is $350.79. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the company earned $9.38 earnings per share. The company’s revenue was up 10.7% on a year-over-year basis. As a group, equities research analysts forecast that Humana Inc. will post 16.27 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on HUM shares. Piper Sandler started coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price target on the stock. TD Cowen dropped their price objective on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Royal Bank of Canada lowered their target price on Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Barclays cut their price target on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. Finally, Jefferies Financial Group decreased their price objective on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research note on Monday, April 22nd. Fourteen analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $409.55.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.